Last updated on October 2018

Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients


Brief description of study

National trial, multicenter, randomized, phase II assessing FOLFIRINOX + Panitumumab versus mFOLFOX6 + Panitumumab in metastatic colorectal cancer patients selected by RAS and B-RAF status from circulating DNA analysis.

Evaluation of complete response rate on treatment combining FOLFIRINOX and panitumumab.

Detailed Study Description

PRIMARY OBJECTIVE: Evaluation of complete response rate on treatment combining FOLFIRINOX and panitumumab

SECONDARY OBJECTIVE(S):

  • Overall Survival
  • Progression free survival
  • Secondary resection
  • Early tumor shrinkage (ETS)
  • Depth of response (DpR)
  • Safety profile (NCI CTCAE v 4.03 classification)
  • Diagnostic performance of ccfDNA analysis compared to the tumor-tissue analysis (current gold standard)

Clinical Study Identifier: NCT02980510

Find a site near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.